Subacute sclerosing panencephalitis

Rare fatal progressive encephalitis caused by persistent measles virus infection

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Subacute sclerosing panencephalitis
Synonyms	SSPE, Dawson disease, Dawson encephalitis, subacute sclerosing leukoencephalitis
Pronounce	N/A
Specialty	Neurology, Pediatrics, Infectious disease
Symptoms	Behavioral changes, cognitive decline, myoclonus, seizures, ataxia, vision loss, dementia
Complications	Severe neurologic disability, coma, vegetative state, death
Onset	Usually years after measles infection
Duration	Progressive
Types	N/A
Causes	Persistent mutated measles virus infection of the central nervous system
Risks	Measles infection at young age, lack of measles vaccination, measles before age 2, immunization gaps, endemic measles exposure
Diagnosis	Clinical history, EEG, MRI, cerebrospinal fluid measles antibody testing, serum measles antibody testing
Differential diagnosis	Progressive multifocal leukoencephalopathy, Creutzfeldt-Jakob disease, mitochondrial disease, autoimmune encephalitis, leukodystrophy, epileptic encephalopathy
Prevention	Measles vaccine, MMR vaccine, high community vaccination coverage
Treatment	Supportive care, seizure control, nutritional support, rehabilitation, investigational or limited antiviral and immunomodulatory therapy
Medication	Anticonvulsants, isoprinosine, interferon alfa in selected cases
Prognosis	Poor; usually fatal
Frequency	Rare in highly vaccinated populations; higher where measles remains endemic
Deaths	N/A

Subacute sclerosing panencephalitis (SSPE) is a rare, progressive, and usually fatal neurologic disorder caused by persistent infection of the central nervous system with a mutated or defective measles virus. It typically appears years after apparent recovery from measles, most often in children, adolescents, or young adults. The disease causes gradual deterioration in behavior, cognition, movement, vision, seizure control, and consciousness.Chapter 7: Measles(link). Centers for Disease Control and Prevention.Subacute Sclerosing Panencephalitis(link). StatPearls, NCBI Bookshelf.

SSPE is one of the most severe long-term complications of measles. It is preventable through effective measles immunization. Because SSPE occurs only after measles virus infection, prevention depends on avoiding measles through MMR vaccine and maintaining high community vaccination coverage.Measles Symptoms and Complications(link). Centers for Disease Control and Prevention.Measles(link). World Health Organization.

Overview

SSPE is a chronic encephalitis caused by persistent measles virus in the brain. The disease usually begins after a long latent period. The person may appear to have fully recovered from measles for many years before neurologic symptoms begin.

The condition is rare in countries with high measles vaccine coverage, but it remains an important concern wherever measles outbreaks occur or vaccination rates fall. Recent measles resurgences in multiple countries have renewed attention to SSPE because children infected with measles today may develop SSPE years later."Subacute Sclerosing Panencephalitis: Impact on Public Health and Vaccination".Brain and Behavior.2025;PMC:11808179."Subacute sclerosing panencephalitis as a re-emerging complication of measles".Journal of Medical Virology.2025;PMC:12145622.

Terminology

• Subacute sclerosing panencephalitis - Progressive inflammatory disease of the brain caused by persistent measles virus.
• SSPE - Common abbreviation for subacute sclerosing panencephalitis.
• Dawson disease - Historical eponym for SSPE.
• Dawson encephalitis - Another historical name for the disease.
• Slow virus disease - Older term for chronic progressive viral diseases with long incubation periods.
• Panencephalitis - Inflammation involving broad areas of the brain.
• Measles virus - Causative virus associated with SSPE.
• Rubeola - Another name for measles.

Cause

SSPE is caused by persistent infection of the brain with measles virus. The virus in SSPE is usually altered, defective, or hypermutated in ways that allow it to remain in the central nervous system while spreading from cell to cell.

• Measles - Acute viral infection that precedes SSPE.
• Measles virus - RNA virus responsible for measles and SSPE.
• Persistent infection - Long-term viral presence in tissue after the acute infection.
• Central nervous system - Brain and spinal cord, the main site of disease in SSPE.
• Neurotropic virus - Virus capable of infecting nervous system tissue.
• Viral mutation - Genetic change in the virus that may contribute to persistence.
• Defective virus - Virus with abnormal replication or protein production.
• Immune evasion - Mechanisms by which virus persists despite host immunity.

SSPE is not caused by the measles vaccine. The disease follows infection with wild-type measles virus. Prevention of measles through vaccination is the most effective way to prevent SSPE.

Risk factors

The most important risk factor is prior measles infection, especially at a young age.

• Unvaccinated status - Increases risk of measles infection and therefore SSPE.
• Measles infection - Required antecedent event for SSPE.
• Measles before age 2 - Associated with higher SSPE risk.
• Infant measles - Measles in infancy carries increased long-term neurologic risk.
• Congenital measles - Measles acquired in utero or around birth may increase severe neurologic risk.
• Low vaccination coverage - Allows measles outbreaks and future SSPE cases.
• Measles outbreak - Creates risk for susceptible infants and unvaccinated persons.
• Immunization gap - Failure to receive timely measles-containing vaccine.
• Measles-endemic region - Regions with ongoing measles transmission have higher SSPE burden.
• Male sex - Some reports describe higher frequency in males.

CDC notes that SSPE generally develops 7–10 years after measles infection and that risk may be higher when measles occurs before the second year of life.Chapter 7: Measles(link). Centers for Disease Control and Prevention.

Pathogenesis

The pathogenesis of SSPE is complex and incompletely understood. It involves persistence of mutated measles virus within neurons and glial cells, abnormal viral protein expression, chronic inflammation, and progressive destruction of brain tissue.

• Neuron - Nerve cell affected by persistent measles virus.
• Glial cell - Supporting nervous system cell that can be involved in viral persistence.
• Nucleocapsid - Viral structure often produced in infected cells.
• Matrix protein - Measles virus protein often abnormal or restricted in SSPE strains.
• Envelope protein - Viral protein involved in viral structure and spread.
• Cell-to-cell spread - Movement of virus between nervous system cells without typical extracellular viral release.
• Demyelination - Loss of myelin that may contribute to neurologic decline.
• Neuroinflammation - Inflammatory response in brain tissue.
• Cortical atrophy - Brain tissue loss seen as disease progresses.
• White matter lesion - MRI finding that may occur in SSPE.

Because infectious viral particles are not produced in a typical way, the virus can persist in the brain for years. Progressive injury eventually leads to cognitive decline, seizures, motor impairment, coma, and death.Subacute Sclerosing Panencephalitis(link). StatPearls, NCBI Bookshelf.

Clinical features

The disease usually begins subtly and progresses over months to years. Early symptoms may be mistaken for behavioral, psychiatric, developmental, or school-related problems.

Early features

• Behavioral changes - Irritability, personality change, mood changes, or decline in social function.
• Cognitive decline - Loss of school performance, memory, attention, or reasoning ability.
• Learning difficulty - New academic decline in a previously functioning child or adolescent.
• Depression - Mood symptoms can occur early.
• Apathy - Reduced motivation or engagement.
• Headache - May occur but is nonspecific.
• Fatigue - Reduced energy or activity level.
• Visual disturbance - Blurred vision or other vision changes may occur early in some cases.

Neurologic progression

• Myoclonus - Sudden brief jerking movements, often characteristic of SSPE.
• Seizure - Focal or generalized seizures may occur.
• Ataxia - Impaired coordination and balance.
• Dystonia - Sustained involuntary muscle contraction.
• Chorea - Irregular involuntary movements.
• Spasticity - Increased muscle tone and stiffness.
• Rigidity - Resistance to passive movement.
• Dementia - Progressive loss of cognitive function.
• Aphasia - Impairment of language.
• Dysphagia - Difficulty swallowing.
• Vision loss - May occur due to retinal or cortical involvement.
• Blindness - Severe visual involvement can occur.
• Coma - Late-stage loss of consciousness.
• Vegetative state - Severe late-stage neurologic outcome.

Stages

SSPE is often described in stages. Staging systems vary, but the following pattern is commonly used.

Stage 1

Stage 1 is the early behavioral and cognitive stage.

• Personality change - New irritability, mood change, or behavioral decline.
• School decline - Loss of academic performance.
• Memory impairment - Early cognitive difficulty.
• Depression - Mood disturbance may occur.
• Subtle neurologic signs - Mild motor or visual symptoms may begin.

Stage 2

Stage 2 is marked by obvious neurologic deterioration.

• Myoclonic seizure - Characteristic jerking episodes.
• Generalized seizure - Seizures may become more frequent.
• Ataxia - Coordination and gait worsen.
• Dementia - Cognitive impairment becomes more apparent.
• Visual impairment - Vision may deteriorate.
• Electroencephalography - Periodic complexes may be seen.

Stage 3

Stage 3 is a severe motor and neurologic disability stage.

• Rigidity - Increased muscle tone.
• Spasticity - Stiffness and abnormal reflexes.
• Dystonia - Abnormal postures or twisting movements.
• Feeding difficulty - Dysphagia and poor intake.
• Immobility - Loss of independent movement.
• Severe dementia - Profound cognitive impairment.

Stage 4

Stage 4 is the terminal stage.

• Coma - Loss of consciousness.
• Autonomic dysfunction - Abnormal heart rate, blood pressure, temperature, or breathing control.
• Respiratory failure - May occur in late disease.
• Aspiration pneumonia - Common late complication in neurologically impaired patients.
• Death - Usually occurs after progressive neurologic decline.

Diagnosis

Diagnosis is based on clinical features, prior measles history or measles exposure, EEG findings, CSF measles antibody testing, serum antibody testing, and neuroimaging. Brain biopsy is rarely needed but may be considered when the diagnosis remains uncertain.

Clinical suspicion

SSPE should be suspected in a child, teenager, or young adult with progressive cognitive decline, behavioral change, and myoclonus, especially with a history of measles infection or incomplete measles vaccination.

• Measles history - Prior measles infection supports the diagnosis but may be absent or forgotten.
• Vaccination history - Lack of measles vaccination increases suspicion.
• Latency period - Neurologic disease typically begins years after measles.
• Progressive neurologic decline - Key clinical feature.
• Myoclonus - Strong diagnostic clue.
• Cognitive decline - Often one of the first clues.

Electroencephalography

Electroencephalography is a major diagnostic test.

• EEG - Often shows periodic, high-amplitude, generalized slow-wave complexes.
• Periodic complex - Repeating pattern that can correlate with myoclonic jerks.
• Epileptiform discharge - May occur in patients with seizures.
• Background slowing - May reflect encephalopathy.
• Serial EEG - Findings may evolve as disease progresses.

Cerebrospinal fluid testing

Cerebrospinal fluid studies are central to diagnosis.

• Cerebrospinal fluid - Usually has normal or mildly abnormal routine parameters.
• Measles antibody - Elevated measles IgG in CSF is a major diagnostic feature.
• Intrathecal antibody synthesis - Production of measles antibody within the central nervous system.
• CSF protein - May be normal or mildly elevated.
• CSF cell count - Often normal or mildly elevated.
• Oligoclonal bands - May be present in some cases.

Serology

• Measles IgG - Serum antibody is usually elevated.
• Measles IgM - Usually not helpful in chronic SSPE.
• Serum-to-CSF ratio - May help demonstrate intrathecal measles antibody production.
• Antibody index - Used in some laboratories to support CNS antibody synthesis.

Neuroimaging

Imaging may support diagnosis and exclude other disorders.

• Magnetic resonance imaging - May show white matter lesions, cortical atrophy, or brainstem involvement.
• Computed tomography - May show cortical atrophy or white matter changes, especially later in disease.
• FLAIR imaging - MRI sequence useful for white matter lesions.
• Diffusion-weighted imaging - May help evaluate active lesions or alternative diagnoses.
• Brain atrophy - May become prominent with progression.
• Occipital lobe - May be involved in patients with visual symptoms.
• Basal ganglia - May be involved in some cases.

Brain biopsy

• Brain biopsy - Rarely required when diagnosis is uncertain.
• Histopathology - May show inflammation, inclusion bodies, demyelination, or viral antigen.
• Immunohistochemistry - Can detect measles viral proteins in tissue.
• Polymerase chain reaction - May detect measles virus RNA in selected tissue samples.

Diagnostic criteria

Several diagnostic approaches combine major and minor features.

• Typical clinical course - Progressive cognitive decline with myoclonus.
• Elevated CSF measles antibody - Major supportive finding.
• Periodic EEG complexes - Characteristic electrophysiologic finding.
• High serum measles antibody - Supportive evidence of prior measles immune response.
• MRI changes - Supportive but not specific.
• Brain biopsy - Reserved for unusual cases.

Differential diagnosis

SSPE can resemble other progressive neurologic disorders.

• Progressive multifocal leukoencephalopathy - JC virus demyelinating disease, usually in immunocompromised patients.
• Creutzfeldt-Jakob disease - Rapidly progressive prion disease.
• Autoimmune encephalitis - Immune-mediated encephalitis with psychiatric, seizure, and cognitive symptoms.
• Mitochondrial disease - Genetic energy metabolism disorders causing neurologic decline.
• Leukodystrophy - Genetic white matter disorders.
• Metachromatic leukodystrophy - Lysosomal storage disorder causing neurologic decline.
• Adrenoleukodystrophy - Peroxisomal disorder with white matter disease.
• Progressive myoclonic epilepsy - Group of disorders causing myoclonus and seizures.
• Rasmussen encephalitis - Chronic focal encephalitis with seizures and neurologic decline.
• HIV encephalopathy - Neurologic disease related to HIV infection.
• Meningoencephalitis - Infectious or inflammatory brain disease.
• Neuronal ceroid lipofuscinosis - Neurodegenerative disorder with seizures and vision loss.
• Wilson disease - Copper metabolism disorder with neurologic and psychiatric features.
• Toxic encephalopathy - Brain dysfunction due to toxins or metabolic derangements.

Treatment

There is no proven cure for SSPE. Management focuses on supportive care, seizure control, nutrition, rehabilitation, prevention of complications, and family support. Some antiviral and immunomodulatory treatments have been used, but evidence is limited and responses are variable.Subacute Sclerosing Panencephalitis(link). StatPearls, NCBI Bookshelf.

Supportive care

• Neurology care - Coordinates diagnosis and symptom management.
• Pediatric neurology - Important for children and adolescents.
• Anticonvulsant therapy - Used for seizures and myoclonus.
• Rehabilitation - Physical, occupational, and speech therapy may support function.
• Nutritional support - Feeding support may be needed as swallowing worsens.
• Aspiration prevention - Important in advanced disease.
• Respiratory care - Needed in late-stage disease.
• Palliative care - Helps manage symptoms, goals of care, and family support.
• Psychological support - Important for patients and caregivers.
• Social work - Helps with disability, home care, and resources.

Antiviral and immunomodulatory therapy

Some treatments have been tried, especially in early disease, but none reliably cures SSPE.

• Isoprinosine - Also called inosiplex; used in some studies and clinical settings.
• Interferon alfa - Has been used intraventricularly or intrathecally in selected cases.
• Ribavirin - Investigational or limited use in some reports.
• Acyclovir - Not generally effective against measles virus.
• Immunomodulatory therapy - Sometimes attempted, but evidence is limited.
• Clinical trial - Participation may be considered where available.
• Early treatment - Outcomes may be better when therapy is attempted early, but benefit remains uncertain.

Seizure and myoclonus management

• Valproate - May be used for myoclonic seizures in selected patients.
• Levetiracetam - Common anticonvulsant used for myoclonus or seizures.
• Clonazepam - May help myoclonus in some cases.
• Antiepileptic drug - Medication choice depends on seizure type, age, adverse effects, and comorbidities.
• Status epilepticus - Requires emergency management.
• EEG monitoring - Helps guide seizure evaluation.

Advanced care

• Gastrostomy tube - May be considered when swallowing is unsafe.
• Pressure injury prevention - Important in immobile patients.
• Contracture prevention - Physical therapy and positioning may help.
• Spasticity management - May involve therapy, medications, or supportive measures.
• Home nursing - May be needed in advanced disease.
• Hospice care - Appropriate when goals shift to comfort-focused care.
• Advance care planning - Helps families make informed decisions.

Prognosis

SSPE usually has a poor prognosis. Most patients develop progressive neurologic decline leading to severe disability, coma, and death. The classic course leads to death within several years, although fulminant, prolonged, and rarely remitting courses have been reported.

• Progressive disease - Most patients worsen over time.
• High mortality - SSPE is usually fatal.
• Fulminant SSPE - Rapid deterioration and death within months can occur.
• Chronic SSPE - Some patients have a slower course over many years.
• Spontaneous remission - Rare stabilization or remission has been reported.
• Vegetative state - Severe late-stage outcome.
• Quality of life - Progressive disability affects the patient and family profoundly.
• Caregiver burden - Long-term neurologic care creates major emotional and practical demands.

Epidemiology

SSPE incidence varies by measles incidence, vaccination coverage, age at measles infection, surveillance quality, and access to healthcare. It is rare in countries with sustained high measles vaccination coverage and more common where measles remains endemic or outbreaks occur.

• Measles vaccination - Reduces SSPE by preventing measles infection.
• Endemic measles - Ongoing measles transmission increases SSPE burden.
• Measles outbreak - May lead to SSPE cases years later.
• Infant infection - Measles in infancy carries particularly high SSPE risk.
• Developed country - SSPE is rare where measles vaccination is widespread.
• Low-resource setting - Higher measles burden can increase SSPE cases.
• Surveillance - Underdiagnosis and underreporting may occur.
• Male predominance - Some studies report more cases in males.

CDC reports that among people who had measles during the 1989–1991 U.S. resurgence, SSPE risk was estimated at 7–11 cases per 100,000 measles cases, with higher risk when measles occurred before age 2.Chapter 7: Measles(link). Centers for Disease Control and Prevention.

Prevention

Prevention of SSPE depends on prevention of measles. There is no intervention after measles infection that reliably prevents SSPE.

• MMR vaccine - Measles, mumps, and rubella vaccine is the main prevention strategy.
• Measles vaccine - Prevents wild-type measles infection and therefore SSPE.
• Herd immunity - High community vaccination coverage protects infants and people who cannot be vaccinated.
• Two-dose vaccination - Two doses provide the best protection against measles in many national schedules.
• Outbreak control - Rapid identification, isolation, contact tracing, and post-exposure measures reduce spread.
• Post-exposure prophylaxis - MMR vaccine or immune globulin may be used after exposure in selected people according to public health guidance.
• Infant protection - Infants too young for routine measles vaccination depend on community immunity.
• Travel vaccination - Travelers should be protected before visiting areas with measles transmission.
• Public health surveillance - Detects measles outbreaks and helps prevent future SSPE cases.

CDC states that two doses of MMR vaccine provide the best protection against measles.About Measles(link). Centers for Disease Control and Prevention.

Public health importance

SSPE is a delayed consequence of measles and therefore reflects measles control failures from years earlier. Even when measles mortality is low, measles infection can produce severe delayed complications.

• Vaccine-preventable disease - SSPE is preventable through measles prevention.
• Measles elimination - Reduces future SSPE cases.
• Vaccine hesitancy - Can increase measles outbreaks and future SSPE risk.
• Immunization registry - Helps identify vaccination gaps.
• School vaccination requirement - Supports community protection in many jurisdictions.
• Global health - Measles and SSPE remain important where vaccine access is limited.
• Health communication - Accurate measles risk communication helps counter misinformation.

History

SSPE was recognized as a progressive post-measles neurologic disease before modern molecular virology clarified its cause. Earlier names include Dawson disease and subacute sclerosing leukoencephalitis.

• Dawson disease - Historical eponym.
• Measles virus - Established cause of SSPE.
• Slow virus disease - Historical concept used to describe delayed progressive viral neurologic illness.
• Electroencephalography - Helped define characteristic periodic EEG abnormalities.
• Measles vaccine - Dramatically reduced SSPE incidence where widely used.
• Molecular virology - Demonstrated persistent mutated measles virus in brain tissue.

Patient education

Families should understand that SSPE is a delayed complication of measles and is not caused by the measles vaccine.

• Measles - Can cause serious complications years after the rash resolves.
• MMR vaccine - Prevents measles and thereby prevents SSPE.
• Early symptoms - School decline, behavior change, or myoclonic jerks after prior measles should prompt medical evaluation.
• Seizure safety - Families should learn seizure first aid.
• Nutrition - Feeding and swallowing should be monitored as disease progresses.
• Rehabilitation - Therapy may help maintain comfort and function.
• Palliative care - Can improve symptom control and family support.
• Genetic disease - SSPE is not inherited; it is a complication of measles infection.
• Contagiousness - SSPE itself is not typically spread person to person, but measles prevention remains essential.
• Care planning - Long-term neurologic care and family support are important.

When to seek medical care

Medical evaluation is important for children, teenagers, or young adults with progressive neurologic decline, especially after measles infection.

• Behavioral changes - New personality or mood change with decline in school or function should be evaluated.
• Cognitive decline - Progressive memory, learning, or attention problems need assessment.
• Myoclonus - Sudden repeated jerks are a major warning sign.
• Seizure - Any new seizure requires medical evaluation.
• Vision loss - New visual symptoms need urgent assessment.
• Ataxia - Worsening balance or coordination should be evaluated.
• Dementia - Progressive cognitive impairment in a young person is abnormal.
• Swallowing difficulty - Raises risk of aspiration.
• Breathing difficulty - Requires urgent care in advanced disease.
• Measles exposure - Unvaccinated or immunocompromised contacts should seek public health guidance.

See also

• Measles
• Measles virus
• MMR vaccine
• Viral encephalitis
• Encephalitis
• Dementia
• Myoclonus
• Seizure
• Electroencephalography
• Cerebrospinal fluid
• Neurodegenerative disorder
• Slow virus disease
• Vaccine-preventable disease
• Herd immunity
• Public health
• Pediatric neurology
• Infectious disease
• Progressive multifocal leukoencephalopathy
• Creutzfeldt-Jakob disease

Further reading

• Chapter 7: Measles(link). Centers for Disease Control and Prevention.
• Measles Symptoms and Complications(link). Centers for Disease Control and Prevention.
• About Measles(link). Centers for Disease Control and Prevention.
• Measles(link). World Health Organization.
• Subacute Sclerosing Panencephalitis(link). StatPearls, NCBI Bookshelf.
• "Subacute sclerosing panencephalitis".Postgraduate Medical Journal.2002;78(916)

63-70.doi:10.1136/pmj.78.916.63.PMID:11807185.PMC:1742261.

• "Subacute Sclerosing Panencephalitis: Impact on Public Health and Vaccination".Brain and Behavior.2025;PMC:11808179.
• "Subacute sclerosing panencephalitis as a re-emerging complication of measles".Journal of Medical Virology.2025;PMC:12145622.

External links

• CDC - Measles surveillance manual
• CDC - Measles symptoms and complications
• CDC - About measles
• WHO - Measles
• NCBI Bookshelf - Subacute Sclerosing Panencephalitis
• NORD - Subacute Sclerosing Panencephalitis
• Postgraduate Medical Journal - Subacute sclerosing panencephalitis
• Brain and Behavior - SSPE impact on public health and vaccination

edit 

WikiMD neurology

External links

• Comprehensive information from the National Institute of health.
  

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z